328 related articles for article (PubMed ID: 25397966)
1. Cost-effectiveness of diabetes pay-for-performance incentive designs.
Hsieh HM; Tsai SL; Shin SJ; Mau LW; Chiu HC
Med Care; 2015 Feb; 53(2):106-15. PubMed ID: 25397966
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of a Diabetes Pay-For-Performance Program in Diabetes Patients with Multiple Chronic Conditions.
Hsieh HM; Gu SM; Shin SJ; Kao HY; Lin YC; Chiu HC
PLoS One; 2015; 10(7):e0133163. PubMed ID: 26173086
[TBL] [Abstract][Full Text] [Related]
3. Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?
Tan EC; Pwu RF; Chen DR; Yang MC
Qual Life Res; 2014 Mar; 23(2):687-96. PubMed ID: 23975377
[TBL] [Abstract][Full Text] [Related]
4. Effects of Changes in Diabetes Pay-for-Performance Incentive Designs on Patient Risk Selection.
Hsieh HM; Tsai SL; Mau LW; Chiu HC
Health Serv Res; 2016 Apr; 51(2):667-86. PubMed ID: 26152649
[TBL] [Abstract][Full Text] [Related]
5. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment.
Lee TT; Cheng SH; Chen CC; Lai MS
Am J Manag Care; 2010 Jan; 16(1):65-9. PubMed ID: 20148607
[TBL] [Abstract][Full Text] [Related]
6. The association between participation in a pay-for-performance program and macrovascular complications in patients with type 2 diabetes in Taiwan: A nationwide population-based cohort study.
Hsieh HM; Lin TH; Lee IC; Huang CJ; Shin SJ; Chiu HC
Prev Med; 2016 Apr; 85():53-59. PubMed ID: 26740347
[TBL] [Abstract][Full Text] [Related]
7. Trend and factors associated with healthcare use and costs in type 2 diabetes mellitus: a decade experience of a universal health insurance program.
Cheng JS; Tsai WC; Lin CL; Chen L; Lang HC; Hsieh HM; Shin SJ; Chen T; Huang CT; Hsu CC
Med Care; 2015 Feb; 53(2):116-24. PubMed ID: 25517075
[TBL] [Abstract][Full Text] [Related]
8. The effect of a PPO pay-for-performance program on patients with diabetes.
Chen JY; Tian H; Taira Juarez D; Hodges KA; Brand JC; Chung RS; Legorreta AP
Am J Manag Care; 2010 Jan; 16(1):e11-9. PubMed ID: 20059287
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment.
Cheng SH; Lee TT; Chen CC
Med Care; 2012 Feb; 50(2):109-16. PubMed ID: 22249920
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients.
Hsieh HM; Lin MY; Chiu YW; Wu PH; Cheng LJ; Jian FS; Hsu CC; Hwang SJ
Nephrol Dial Transplant; 2017 Jul; 32(7):1184-1194. PubMed ID: 28486670
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Pay-for-Performance Incentive Designs on Diabetes Care.
Hsieh HM; Shin SJ; Tsai SL; Chiu HC
Med Care; 2016 Dec; 54(12):1063-1069. PubMed ID: 27479599
[TBL] [Abstract][Full Text] [Related]
12. Using financial incentives to improve the care of tuberculosis patients.
Lee CY; Chi MJ; Yang SL; Lo HY; Cheng SH
Am J Manag Care; 2015 Jan; 21(1):e35-42. PubMed ID: 25880266
[TBL] [Abstract][Full Text] [Related]
13. Assessing Taiwan's pay-for-performance program for diabetes care: a cost-benefit net value approach.
Lu JR; Chen YI; Eggleston K; Chen CH; Chen B
Eur J Health Econ; 2023 Jul; 24(5):717-733. PubMed ID: 35995886
[TBL] [Abstract][Full Text] [Related]
14. Disease-specific Pay-for-Performance Programs: Do the P4P Effects Differ Between Diabetic Patients With and Without Multiple Chronic Conditions?
Huang YC; Lee MC; Chou YJ; Huang N
Med Care; 2016 Nov; 54(11):977-983. PubMed ID: 27547944
[TBL] [Abstract][Full Text] [Related]
15. The effects of pay-for-performance on tuberculosis treatment in Taiwan.
Li YH; Tsai WC; Khan M; Yang WT; Lee TF; Wu YC; Kung PT
Health Policy Plan; 2010 Jul; 25(4):334-41. PubMed ID: 20207703
[TBL] [Abstract][Full Text] [Related]
16. Factors related to continuing care and interruption of P4P program participation in patients with diabetes.
Yen SM; Kung PT; Sheen YJ; Chiu LT; Xu XC; Tsai WC
Am J Manag Care; 2016 Jan; 22(1):e18-30. PubMed ID: 26799201
[TBL] [Abstract][Full Text] [Related]
17. Participating physician preferences regarding a pay-for-performance incentive design: a discrete choice experiment.
Chen TT; Lai MS; Chung KP
Int J Qual Health Care; 2016 Feb; 28(1):40-6. PubMed ID: 26660443
[TBL] [Abstract][Full Text] [Related]
18. Effects and Factors Related to Adherence to A Diabetes Pay-for-Performance Program: Analyses of a National Health Insurance Claims Database.
Chi MJ; Chou KR; Pei D; Hwang JS; Quinn L; Chung MH; Liao YM
J Am Med Dir Assoc; 2016 Jul; 17(7):613-9. PubMed ID: 27073041
[TBL] [Abstract][Full Text] [Related]
19. Managing pay for performance: aligning social science research with budget predictability.
Rosenau PV; Lal LS; Lako C
J Healthc Manag; 2012; 57(6):391-404; discussion 404-5. PubMed ID: 23297606
[TBL] [Abstract][Full Text] [Related]
20. Does the pay-for-performance programme reduce the emergency department visits for hypoglycaemia in type 2 diabetic patients?
Yu HC; Tsai WC; Kung PT
Health Policy Plan; 2014 Sep; 29(6):732-41. PubMed ID: 23894069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
